Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus - Wikidata - wikimedia - TriplyDB

Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus

Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus

http://www.wikidata.org/entity/Q35921668

about

Protease-resistant peptide design-empowering nature's fragile warriors against HIV Structural and biological mimicry of protein surface recognition by / -peptide foldamers Design of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance Broad Distribution of Energetically Important Contacts across an Extended Protein Interface The M-T Hook Structure Is Critical for Design of HIV-1 Fusion Inhibitors Broad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor Sifuvirtide Discovery of Critical Residues for Viral Entry and Inhibition through Structural Insight of HIV-1 Fusion Inhibitor CP621-652 Enhancement of α-Helix Mimicry by an α/β-Peptide Foldamer via Incorporation of a Dense Ionic Side-Chain Array Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding Analysis and prediction of highly effective antiviral peptides based on random forests A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy Design and characterization of swapped-domain constructs of HIV-1 glycoprotein-41 as receptors for drug discovery.Multivalent presentation of antihantavirus peptides on nanoparticles enhances infection blockade Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors.Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK.Origins of resistance to the HIVgp41 viral entry inhibitor T20.Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases.Viral entry inhibitors targeted to the membrane site of action.Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses.Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.HIV entry inhibitors and their potential in HIV therapy Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation.Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potency Disruption of Bcr-Abl coiled coil oligomerization by design.Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.

P2860

Q27010058-1C8B9E49-5C14-4796-A4E3-7F626D6BF355 Q27657158-26BC33D2-FF28-4123-B1C0-DB3F42FABA4E Q27664086-704B3EB6-64B6-4D69-9C4C-A1AB34F0021D Q27666255-17450F0D-2BC9-41C6-877B-85D7305FA6F6 Q27671434-2B57BB19-FA3C-4889-BB78-B269CF92F49B Q27676641-823F0DA7-0B16-4928-B78B-B289066BA129 Q27678581-B23D7BFA-5F1F-4B95-840F-7772DE60D640 Q27678660-389EA02C-05FF-4F18-8C9B-5371774F913A Q28471980-05088247-71E2-41ED-B94D-A5FC72319641 Q28535105-9979C06E-03C3-43E5-9980-DEC3D9402F9B Q28728917-85758A90-0D08-4777-950B-C1DF7481AA0D Q28729918-3AC42AB5-A471-435E-B6EF-918F2758A7E5 Q30661709-A6674F85-B5CF-4E62-8C99-1ADB72347B48 Q30912819-0D704A9A-A6C4-4F92-878B-8E2FF7521301 Q33327051-6E1D393E-AD45-4DA3-976F-F30D50AD9E5A Q33429777-B5EB01AF-4EFE-4D80-8F07-29B66A3C4832 Q33613769-B2AD6A44-E879-4C04-BA73-D7863327B6E4 Q33713101-4E3B3027-56AB-48EC-A1A1-4DAD511A48B1 Q33840121-BB5CFCA0-48CE-4A75-9512-5FCD83A44226 Q33951142-F070E66D-C99B-496A-BDD2-E89EE4D48F25 Q33990602-5CEA737E-C3BC-448E-83A9-52BA4E30D271 Q34055847-2ABFBC0D-3AED-4E4E-9D4B-76E8C00962DD Q34059855-0B76C610-B8C9-4292-8BD3-50F8C8EEB278 Q34069846-F73624C0-7CB8-4450-BD51-A70EE3342F27 Q34150117-361003FD-1666-4745-8824-AF82B62D1518 Q34182763-AE61DCA9-2697-445F-9EC7-29D64333D810 Q34189558-1A747D58-19A0-4436-9B10-F59B01953D9D Q34229664-B44F2FE2-0661-4E08-A72A-3982671D4F6C Q34298481-CF16DBD0-1CEE-4EDA-96EE-FE0CD0014AB9 Q34385987-0B102B7B-67D1-48A0-AE2B-571216B0C476 Q34517381-91C190D9-C4BE-4081-969F-E310921A88CE Q34536817-BD9F6950-B773-44E3-BF41-338E7DF9CE36 Q34595921-F9D3F846-4DAA-410F-90F8-757D5F22FE61 Q34683447-CED1AF13-3E74-4BB6-889E-12CB1A370886 Q34800822-08AB5D63-DBC6-49F7-B2BB-FBE1A2EC8677 Q35145034-F59AF171-DA83-4FAB-ABFD-A206D0CA7104 Q35563298-BF57D124-173C-4D82-99B5-D4C216EB5203 Q35615810-0F05F574-0BC3-4595-BF2C-D51C7F0A5417 Q35641194-AAA99FD2-41FB-46F1-BE63-2C297F2892D8 Q35787743-29749BC5-84C5-4551-9E6A-A08E40F3C73E

P2860

Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus

http://www.wikidata.org/entity/Q35921668

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Design of helical, oligomeric ...... st enfuvirtide-resistant virus

@ast

Design of helical, oligomeric ...... st enfuvirtide-resistant virus

@en

type

label

Design of helical, oligomeric ...... st enfuvirtide-resistant virus

@ast

Design of helical, oligomeric ...... st enfuvirtide-resistant virus

@en

prefLabel

Design of helical, oligomeric ...... st enfuvirtide-resistant virus

@ast

Design of helical, oligomeric ...... st enfuvirtide-resistant virus

@en

P1433

Q35921668-13EDB66F-3E34-454B-8BD9-18BE42C8F12C

P1476

Q35921668-6AAB3491-35F7-4953-927B-2A5383BE1326

P2093

Q35921668-0F2CBFA3-6B3B-4A9F-9206-06665FE7A9B0

Q35921668-69C52092-C2E8-4903-B5F9-679240A42E0C

Q35921668-786E78CC-F1B0-4061-8B35-E452FF0C523D

Q35921668-89C28B51-0D62-443B-9ABF-8BB5FDC6CEA6

Q35921668-AE50EB60-668A-4AEF-9828-B9D283FFB5C8

Q35921668-C00891AF-C409-4B32-8F1B-9E2E2F5A8F8D

Q35921668-CB232EAE-1CB4-4DA3-8447-FBC7B0C7300C

Q35921668-DDD3BACF-C7AB-4A58-B1AE-13F85D19CB81

Q35921668-E400FCF1-20EC-454B-B4A7-E37C61F3A037

Q35921668-E66355EB-938B-494D-A711-91B4A058942D

P2860

Q35921668-0C4844C4-C000-41FB-8931-E3707F912F16

Q35921668-123B5A91-296F-4785-8B32-78C8E8A5B5D2

Q35921668-20BF5755-CC7D-4461-A78E-1186BBF35A96

Q35921668-35DF2691-DEC0-49E5-8F69-1778279D2545

Q35921668-36200761-18A1-4F4C-AF8E-AE9FEBED3A11

Q35921668-3AE6C5C1-9023-4FCD-A6FF-9D02AD8B17F0

Q35921668-43636F2A-4A95-454B-BBF2-80634DBFBCAC

Q35921668-442BF8A4-5AF6-4411-B67A-D9D01A862576

Q35921668-45D898B1-4A97-4C75-89B5-E4A747D8758B

Q35921668-4E19808E-8264-49E1-B7A8-D9FA5ECD6FE3

P304

Q35921668-1FE7ADDC-E065-4724-B31F-6B3C9F9CD495

P31

Q35921668-34BEDD1D-FA19-4035-A747-369254F5AB4D

P356

Q35921668-9B93F389-D38F-45A4-A7B4-9F86A2B4683E

P407

Q35921668-FA67DC39-C289-4E24-9B9B-D626AB31E1F9

P433

Q35921668-2C30A17C-5176-4ED0-9B3C-CEE0D476BA40

P478

Q35921668-95F5B17B-7D48-4AA1-AEF5-EAD21C4AB0FF

P577

Q35921668-9F5BD0BF-CA54-4498-86D3-692B9561B7FE

P5875

Q35921668-F3419E54-A45B-4F78-A455-F6678A08F274

P698

Q35921668-3BC1EA06-D26B-47E7-B9FA-AFC7FB1D6475

P921

Q35921668-37D64387-6B8A-454B-9454-419FC73C3404

P932

Q35921668-13FCF891-5654-4596-93DD-9028CFD43F44

P356

PNAS.0701478104

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Design of helical, oligomeric ...... st enfuvirtide-resistant virus

@en

P2093

Donna K Davison

http://www.w3.org/2001/XMLSchema#string

Jennifer E Seedorff

http://www.w3.org/2001/XMLSchema#string

John J Dwyer

http://www.w3.org/2001/XMLSchema#string

Karen L Wilson

http://www.w3.org/2001/XMLSchema#string

Mary K Delmedico

http://www.w3.org/2001/XMLSchema#string

Michael L Greenberg

http://www.w3.org/2001/XMLSchema#string

Nicolai A Tvermoes

http://www.w3.org/2001/XMLSchema#string

Stephanie A Freel

http://www.w3.org/2001/XMLSchema#string

Stephen A Wring

http://www.w3.org/2001/XMLSchema#string

Thomas J Matthews

http://www.w3.org/2001/XMLSchema#string

P2860

Helix capping in the GCN4 leucine zipper

Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket

Short constrained peptides that inhibit HIV-1 entry

Core structure of gp41 from the HIV envelope glycoprotein

Atomic structure of the ectodomain from HIV-1 gp41

HIV entry and its inhibition

Empirical predictions of protein conformation

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target

Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism

P304

12772-12777

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0701478104

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2007-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6197530

http://www.w3.org/2001/XMLSchema#string

P698

17640899

http://www.w3.org/2001/XMLSchema#string

P921

membrane fusion involved in viral entry into host cell

P932

1937542

http://www.w3.org/2001/XMLSchema#string